Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19180206 | 0.96 | — | — | |
| SCHEMBL26751261 | 0.96 | MEN1 (0.56) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL624587 | 0.96 | — | — | |
| SCHEMBL12009416 | 0.94 | MEN1 (0.75) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| SCHEMBL31424572 | 0.93 | MEN1 (0.53) | MEN1KMT2AGAAKDM4ECYP2C9 | |
| Hydrochloric Acid SCHEMBL2754270 | 0.93 | — | — | |
| SCHEMBL13602344 | 0.90 | — | — | |
| SCHEMBL59122 | 0.90 | — | — | |
| SCHEMBL1635363 | 0.90 | — | — | |
| SCHEMBL26751260 | 0.90 | MEN1 (0.69) | MEN1KMT2AGAAKDM4ECYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461327-B2 | Diamine salts of carboxylic acids | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-06-11 | — | — | US | claimed |
| US-20110028712-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-02-03 | — | — | US | claimed |
| EP-2276840-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP Assets B.V. (NL) | 2011-01-26 | — | — | EP | claimed |
| WO-2009121869-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP ASSETS B.V. (NL) | 2009-10-08 | — | — | WO | claimed |
| US-9718834-B2 | Processes and intermediates for making a JAK inhibitor | INCYTE CORPORATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20170015674-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | INCYTE CORPORATION | 2017-01-19 | — | — | US | disclosed |
| US-8461327-B2 | Diamine salts of carboxylic acids | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-06-11 | — | — | US | disclosed |
| US-8461327-B2 | Diamine salts of carboxylic acids | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-06-11 | — | — | US | disclosed |
| CN-102046800-A | Diamine salts of carboxylic acids | DSM IP ASSETS BV | 2011-05-04 | — | — | CN | disclosed |
| US-20110028712-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-02-03 | — | — | US | disclosed |
| US-20110028712-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2011-02-03 | — | — | US | disclosed |
| EP-2276840-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP Assets B.V. (NL) | 2011-01-26 | — | — | EP | disclosed |
| EP-2276840-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP Assets B.V. (NL) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009121869-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP ASSETS B.V. (NL) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121869-A1 | DIAMINE SALTS OF CARBOXYLIC ACIDS | DSM IP ASSETS B.V. (NL) | 2009-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015674-A1 | PROCESSES AND INTERMEDIATES FOR MAKING A JAK INHIBITOR | JAK1, JAK2, JAK3 | MEN1 1782/4885KMT2A 663/4885GAA 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.